---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000093"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T19:05:32.113536+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio promotes Geoffrey Lynn to CSO; Nadège Pelletier steps down

## Summary
- Nadège Pelletier to step down as Chief Scientific Officer effective Feb 2, 2025; she served since early 2023.
- Geoffrey Lynn, M.D., Ph.D. promoted to CSO effective Dec 1, 2024; he is co-inventor of SNAP-TI technology.
- Lynn previously led Avidea Technologies (acquired by Barinthus in 2021) and holds M.D. from Johns Hopkins, D.Phil. from Oxford.
- Company highlights pipeline progress: VTP-300 in chronic hepatitis B, VTP-1000 (SNAP-TI) in Phase 1 for celiac disease.
- Transition expected to be smooth; Pelletier will remain until responsibilities transitioned.

## SEC filing metadata
- accession: 0001828185-24-000093
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000093/0001828185-24-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000093/brns-20241125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000093
- JSON: https://secwatch.observer/filing/0001828185-24-000093.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000093.txt

## Key facts
- Executive change
  Nadège Pelletier departed as Chief Scientific Officer at Barinthus Biotherapeutics plc..
  - Action: step down
  - Role: Chief Scientific Officer
  source text: On November 25, 2024, Nadège Pelletier, Ph.D., notified Barinthus Biotherapeutics plc (the "Company") that she will step down as Chief Scientific Officer of the Company effective February 2, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000093/0001828185-24-000093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.